Skip to the guide
KLOW Window Guide

What is KLOW peptide made of?

The name fits on a label. Understanding it takes a little more room.

Four differently tinted panes reflect one morning street along a closed market arcade.

One name, four ingredients

KLOW is a blend of GHK-Cu, TB-500, KPV and BPC-157. They remain separate substances when mixed. There isn't a single KLOW molecule with one known effect.

You may also see the word stack. It means the ingredients are grouped together. It doesn't mean a study has shown that the group works better than any ingredient alone.

KPV brings in the gut lining

KPV is a peptide, a small chain of amino acids. Its three letters name the amino acids lysine, proline and valine. The gut lining, or mucosa, is one place researchers have studied it.

In lab cells and mice, KPV reduced signs of inflammation. The mice received KPV in drinking water. That's a finding about one ingredient in those settings, with no human KLOW result attached.

The other ingredients have different stories

BPC-157 is a lab-made peptide with a history of gut research, including stomach ulcers in rats. GHK-Cu pairs a small peptide with copper. Much of its familiar research concerns skin.

A review of GHK skin research describes findings from lab work and products applied to skin. Neither that work nor a rat stomach experiment tells us what the whole KLOW blend does in people.

TB-500 needs its full name checked

A lab makes TB-500 by copying a small section of thymosin beta-4 and adding a chemical cap. In its TB-500 review, FDA found no published study of people receiving TB-500. It cautions against swapping the two names.

So when a paper says thymosin beta-4, I keep that name on the finding. This isn't a spelling quibble. A study of a different substance can't answer the question just because the names look related.

Mixing leaves a big question

No controlled study has tested the four-part KLOW blend. The ingredients' separate findings explain why someone might investigate it. They don't show that mixing them helps, or establish the mixture's safety.

FDA's KPV assessment also raises possible immune reactions and peptide clumping. These are unresolved risks, not measured rates of harm. The effects page puts the safety questions beside the hoped-for benefits.

What the label can tell you

The exact ingredients are a useful start. Next comes the paper: what substance did it test, who or what received it, and how? A confident claim can read very differently once the study's setting is clear.

KLOW has no FDA-approved combination product. FDA explains that compounded medicines lack its approval. A prescription decision and proof that a blend works are different questions; reading one word on a label won't settle both.